Ruxolitinib + Ulixertinib combination

Current understanding

To be populated as evidence accumulates.

2026-02-13 — Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: cross-connection with erk-inhibitor-astx029-mpn: Both regimens target ERK/MAPK signaling in myeloid disease — ASTX029+ASTX727 in RAS-mutant MDS/MDS-MPN, and ulixertinib+ruxolitinib in MPN — reflecting parallel strategies to exploit ERK dependency. (novelty: 4)
2026-04-03 — A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis: Phase I/II dose-escalation trial (trial-early) evaluating ulixertinib (selective ERK1/2 inhibitor) added to ruxolitinib in myelofibrosis — first-in-class JAK + ERK1/2 combination targeting MAPK reactivation as a downstream escape pathway from JAK inhibition. (novelty: 4)